Epigenetic Dual Targeting

About CheMedImmune

CheMedImmune is a private, preclinical-stage biotech targeting significant unmet needs in oncology, specifically cancers resistant to current immunotherapies like colorectal and pancreatic cancer. The company leverages insights into immune checkpoint biology and epigenetic regulation to develop three core platforms: osteopontin (OPN)-blocking antibodies, a lipid nanoparticle DNA therapy for lung metastases, and epigenetic dual-targeting strategies. Led by a small, scientifically-driven team with strong publication records and an early patent, the company is positioned to address large markets but faces the typical high risks of early-stage drug development.

Therapeutic Areas